The EPIC Study showed a significant benefit in
administering pimobendan in dogs with preclinical myxomatous mitral valve disease (MMVD)-- before the onset of congestive heart failure (CHF) cardiac - related death, or euthanasia (composite primary endpoint).
Not exact matches
Recent results from the EPIC Study, however, show that
pimobendan, when
administered to dogs in stage B2 — before clinical signs of heart failure appear — succeeded in delaying the onset of CHF.
Dogs were
administered conventional treatments with or without
pimobendan.
There was no difference in survival between dogs
administered standard and low doses of
pimobendan, but
pimobendan did prevent the reoccurrence of pulmonary edema in a dose - dependent manner.